



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ³ : A61K 31/05, 7/42		A1	(11) International Publication Number: WO 85/00106 (43) International Publication Date: 17 January 1985 (17.01.85)
(21) International Application Number: PCT/US84/00896			(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), JP, KP, LU (European patent), NL (European patent), SE (European patent).
(22) International Filing Date: 11 June 1984 (11.06.84)			
(31) Priority Application Numbers: 506,414 585,515			
(32) Priority Dates: 21 June 1983 (21.06.83) 2 March 1984 (02.03.84)			Published <i>With international search report.</i>
(33) Priority Country: US			
(71) Applicant: STIEFEL LABORATORIES, INC. [US/US]; 2801 Ponce de Leon Boulevard, Coral Gables, FL 33134 (US).			
(72) Inventors: STIEFEL, Werner, K. ; NICOLAI, Daniel, W. ; 2801 Ponce de Leon Boulevard, Coral Gables, FL 33134 (US).			
(74) Agent: COLLINS, Bruce, M.; P.O. Box 112-M, Morristown, NJ 07960 (US).			

(54) Title: IMPROVED COMPOSITIONS FOR THE TREATMENT OF PSORIASIS

(57) Abstract

A topical anthralin cream composition in which the anthralin demonstrates improved stability, comprises from about 0.05 % to about 5 % by weight of anthralin in a water:fluid hydrocarbon emulsion having a weight ratio of at least about 5:1, at least one anionic emulsifying agent, at least one oil soluble anti-oxidant, at least one water soluble acidic material, and at least one bifunctional sequestering agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	KR	Republic of Corea
AU	Australia	LI	Liechtenstein
BE	Belgium	LK	Sri Lanka
BG	Bulgaria	LU	Luxembourg
BR	Brazil	MC	Monaco
CF	Central African Republic	MG	Madagascar
CG	Congo	MR	Mauritania
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SD	Sudan
FR	France	SE	Sweden
GA	Gabon	SN	Senegal
GB	United Kingdom	SU	Soviet Union
HU	Hungary	TD	Chad
JP	Japan	TG	Togo
KP	Democratic People's Republic of Korea	US	United States of America

-1-

Description

IMPROVED COMPOSITIONS FOR THE TREATMENT OF PSORIASIS

Technical Field

5 The present invention pertains to topical compositions of anthralin for use in treating psoriasis.

Background Art

10 1,8,9-Trihydroxyanthracene, also known as dithranol or anthralin, is one of the few effective agents available for the treatment of psoriasis. The compound, however, exhibits high irritancy to skin which is not afflicted with psoriasis, undesirable staining properties, and a tendency to be oxidized, leading to product instability. Historically, the compound has been formulated in heavy pastes and ointments such as Lassars 15 paste and emulsifying ointments.

The utilization of oxalic acid to stabilize anthralin composition is described in U.S. Patent No. 4,367,224. Such compositions are however anhydrous and take the form of a congealed yellow ointment.

20 The topical composition described in U.S. Patent No. 4,203,969 represents a cosmetically more elegant anthralin formulation than prior formulations. Moreover, the spreadable composition described in that patent appears to satisfy some stability critieria in 25 that excessive decomposition is not discernible upon U.V. analysis. More sophisticated analysis of this formulation, however, indicates that it is subject to undesirable transformations with the passage of time. In particular, high performance liquid chromatography 30 (HPLC) has shown that although the overall pharmaceutical formulation appears to retain its stability, the anthralin dispersed in the oil phase undergoes unacceptable chemical change, not only reducing its effective concentration but also producing degradation 35 products of unknown efficacy. While the structure of

-2-

anthralin break-down product(s) has not yet been fully elucidated, current evidence strongly suggests dimer formation; see e.g. Caron et al., Brit. J. Derm., (1981) 105, Suppl. 20, 57.

5 Disclosure of Invention

The present invention pertains to improved aqueous anthralin formulations which are cosmetically acceptable and which exhibit significantly reduced chemical degradation of active ingredient, as compared 10 with the prior art formulation.

The formulation described herein has certain features in common with the prior formulations of United States Patent No. 4,203,969. In particular, it utilizes a two phase system of water and a hydrocarbon material. 15 Moreover, the desirability of a water soluble acidic component such as citric acid or sodium bisulfite has been confirmed.

The present formulation, however, rather than utilizing a large proportion of hydrocarbon material as 20 the anthralin-carrying phase, employs a predominantly aqueous vehicle, the ratio of water to hydrocarbon being at least on the order of 5:1. Secondly, the hydrocarbon, rather than being of the nature of the semi-solid petrolatum employed in the prior art, is largely 25 fluid. Thirdly, the formulation includes at least one anionic emulsifier. Notwithstanding the high water content, the foregoing produces a high internal phase emulsion having an oil continuous phase and a water disperse phase. Fourthly, rather than utilizing a water-soluble, 30 oil-insoluble antioxidant, the present composition employs precisely the opposite, namely an antioxidant which is oil soluble. Fifthly, the present composition includes a bifunctional sequestering agent.

Best Mode For Carrying Out The Invention

35 In particular, the present invention pertains to an anthralin cream composition which comprises:

(a) (i) from about 0.05% to about 5%,

-3-

by weight of the composition,
of anthralin in

5 (ii) a water: fluid hydrocarbon emulsion
wherein the weight ratio of water to
fluid hydrocarbon is at least about
5:1 but which has an oil continuous
phase;

10 (b) an emulsifying amount, up to about 3%,
by weight of the composition, of at
least one anionic emulsifier;

(c) from about 0.02% to about 2% by weight
of the composition of at least one oil-
soluble antioxidant;

15 (d) from about 0.5% to about 1%, by weight
of the composition, of at least one
acidic material; and

(e) from about 0.02% to about 2% by weight
of the composition of at least one bi-
functional sequestering agent.

20 In addition to the foregoing components, the
present composition advantageously can include one or
more polyols such as glycerol, propylene glycol, sorbi-
tol and the like, one or more hydroxybenzoic acid or
alkyl(C₁-C₄) hydroxybenzoate preservatives such as
25 salicylic acid, methylparaben, ethylparaben, and propyl
paraben, and up to about 6% of an emulsifying agent
which may be either, or preferably both, of a fatty al-
cohol and a non-ionic emulsifier.

30 The desirability of incorporating an antioxi-
dant has been recognized in the prior art, but its role
appears to have been directed towards curtailing oxida-
tion of lipophobic components of the emulsifying agent.
The requirement that the antioxidant be water soluble
and oil-insoluble precluded that component from exerting
35 its properties in the discontinuous hydrocarbon (oil)
phase where the anthralin was primarily distributed.
Although not wishing to be bound by any particular
theory, it is believed that the large proportion of



-4-

hydrocarbon material in the prior art composition reduced (but did not eliminate) decomposition by providing a high dilution factor for the anthralin. This, coupled with the semi-solid nature of the hydrocarbon, would 5 result, by simple chemical kinetic principles, in a reduced incident of the reaction(s) involved in decomposition of active compound, whether the reaction was mediated by oxygen or otherwise. The relatively high content of hydrocarbon which consequently remained on 10 the skin upon evaporation of the water phase, however, necessarily limited the effective concentration of active ingredient and moreover produced an oily, difficultly spreadable composition.

The present invention is based in part on the
15 discovery that while the presence of an antioxidant is
important to the stability of such anthralin emulsion
formulations, it must be soluble in the hydrocarbon
phase if the decomposition of the anthralin itself is to
be inhibited. Unexpectedly, this discovery also has
20 permitted a significant reduction in the proportion of
hydrocarbon material (relative to the aqueous phase), as
well as the use of more fluid hydrocarbon material.

Despite this significant reduction in the hydrocarbon content, the hydrocarbon component(s) constitutes the continuous phase of the emulsion. The hydrocarbon continuous phase is achieved by utilizing one or more anionic emulsifiers, preferably fatty acid metal soap emulsifiers such as aluminum, calcium or magnesium stearate and/or a phosphonic ester salt of a mono- or diglyceride. The amount of emulsifier present will be at least that necessary to provide a stable emulsifying effect, which amount generally need be no more than about 3%, often less.

The use of such emulsifiers in high internal
35 phase water-in-oil emulsions in cosmetic formulations is
described in U.S. Patent No. 4,104,403. However,
anionic emulsifiers prima facie would not appear to lend
themselves to anthralin formulations since trace amounts

-5-

of metals catalyse or initiate the decomposition of anthralin. However by incorporating an oil-soluble antioxidant in the formulation and by further providing at least one bifunctional sequestering agent, it is possible to formulate a high internal phase oil emulsion formulation of anthralin which not only demonstrates improved stability of both overall composition and active ingredient, but also has an esthetically pleasing cream-like cosmetic consistency permitting it to be easily spread and readily absorbed.

Suitable oil soluble antioxidants include such material as ascorbyl palmitate, alpha tocopherol, butylated hydroxytoluene, hydroxyquinone, and butylated hydroxyanisole. The amount included will depend upon the antioxidant potency of the material employed but generally a range from about 0.02 to about 2% by weight is satisfactory. It is not only possible but often desirable to employ several antioxidants in which case the content of each can be reduced. For example, satisfactory stabilization can be achieved by utilizing a three component oil soluble antioxidant mixture of approximately equal amounts of tocopherol, BHT and ascorbyl palmitate; e.g., 0.07% tocopherol, 0.05% BHT and 0.05% ascorbyl palmitate.

Desirably the formulation will contain other emulsifying agents such as higher alkanols; e.g., octyldecanol, particularly 2-octyldecanol and non-ionic surfactants such as polyglycerol oleate, glycerol oleate, propylene glycol cocoate, polyoxyethylene and polyoxypropylene ethers and esters such as polyoxypropylene stearyl ether. The amount of such additional emulsifying agents which can be present will vary depending upon the effectiveness of the particular agent or combination. Significantly, however, because of the reduction of the hydrocarbon material which has been achieved and the use of the metal soap, the total amount of non-ionic emulsifiers can be significantly reduced and seldom need exceed about 5% by weight. In fact in the



SURSTI,--

-6-

preferred embodiment, the amount will be below 5%, e.g., from about 1 up to about 4.5%.

The hydrocarbon material typically will include one or more light mineral oils. Semi-solid hydrocarbons and paraffin can be dissolved therein but the proportion of these relative to the liquid hydrocarbon should not be so great that the overall hydrocarbon component loses its fluid nature. The hydrocarbon component acts as a solubilizer for the anthralin and its fluid nature permits the active ingredient to be easily spread and to penetrate the involved area. Typically, the total content of the fluid hydrocarbon in the composition, which includes normally solid hydrocarbon dissolved in normally liquid hydrocarbon, will be on the order of 10 to 15% by weight whereas the water content will be at least about 75% by weight and preferably about 80%. Hence a typical formulation could have 10.6% of a 2.3:2.3:6.0 mixture of petrolatum, paraffin and light mineral oil and 81% water, the ratio of water to hydrocarbon being about 7.6:1.

In addition to the foregoing components, there will be one or more water soluble components which satisfy at least one of the categories of an acidic material in an amount of from about 0.5% to about 1% by weight of the composition; and at least one bifunctional sequestering agent in an amount of from about 0.02% to about 2% by weight of the composition, both of said functional categories being satisfied.

Acidic materials are typically topically acceptable weak organic acids and weak inorganic acids and acid salts; e.g., malic acid, citric acid, salicylic acid, and sodium metabisulfite. Two or more such materials can be used in amounts of from 0.5% to 1% of the composition.

The bifunctional sequestering agent component includes such materials as disodium ethylenediamine tetraacetic acid and related chelating agents, thiourea, thioacetic acid, cysteine, tyrosine, nicotinic acid and

-7-

sarcosine. Again, two or more such sequestering agents can be employed, the total content of which will range from about 0.02 to about 2% by weight.

Both functional categories must be satisfied

5 but can be satisfied by the same compound. Thus some substances theoretically can fall within both categories of components and serve two functions. For example, malic, salicylic and citric acids, while acidic substances, can also serve as sequestering agents. (Salicylic acid also can functions as a hydroxylated benzoic acid derivative). The acidic material sodium metabisulfite, on the other hand, is not a sequestering agent so that a further component to satisfy this second functional category must be present. Several materials in each

10 15 category can be present.

The composition is prepared by forming a hydrocarbon phase and an aqueous phase into which phases are added the various components. The selection of the phase to which a component is to be added is made on the basis of the component's preferential solubility; i.e., 20 whether it is predominately hydrophobic or hydrophilic. Heat can be utilized to facilitate production of homogeneous individual phases and the homogenizing of the combined two phases to produce the emulsion. Any materials 25 which are sensitive to excessive heat, such as tocopherol or tocopherol acetate, can be added subsequently.

Typical formulations utilizing the principles of this invention are as follows:

Example 1

30 To 120g of light mineral oil are added 46g of petrolatum and 46g of paraffin. Fourteen grams of aluminum stearate are added to this hydrocarbon mixture as emulsifier, together with 30g of polyglyceryl oleate and 60g of 2-octyldodecanol. There then are added 4.8g of 35 anthralin and 0.4g of ascorbyl palmitate as one oil soluble antioxidant. Finally, 8 grams of salicylic acid are added and the whole is thoroughly blended at 90°C. This

-8-

hydrocarbon phase will weigh approximately 330g and will constitute approximately 16.5% of the final composition.

Separately, 1,646g of deionized water are heated to approximately 90°C and 18g of citric acid are 5 dissolved therein. To this is added 1.2g of disodium ethylenediamine tetracetic acid and 5g of a 1.5:1 mixture of methylparaben and ethylparaben. When this aqueous mixture, which will weigh about 1,670g and will constitute approximately 83.5% of the final composition, 10 is homogenous, it is combined with the above hydrocarbon component in a homogenizer. When the emulsion is thoroughly blended, it is cooled to 50°C and 0.6g of tocopherol acetate are added. This mixture is further blended to produce 2,000g of a 0.2% homogenous anthralin 15 cream which maintains its formulation stability and in which the anthralin does not appear to undergo excessive degradation, e.g. less than 10% as determined by HPLC.

Example 2

20 A 0.2% anthralin formulation is prepared according to the procedure of Example 1 utilizing the following components:

Oil phase:

25	mineral oil	6.0%
	paraffin	2.3%
	petrolatum	2.3%
	aluminum stearate	0.7%
	glyceryl oleate	1.5%
	anthralin	.22%
30	ascorbyl palmitate	.02%
	octyldodecanol	3.0%
	salicylic acid	0.4%

Water phase:

35	deionized water	68.82%
	citric acid	0.9%
	Na ₂ EDTA	0.06%
	sorbitol (70%)	13.5%
	methyl paraben	0.15%
	propyl paraben	0.10%
	Alpha tocopherol	0.03%

-9-

Example 3

A formulation is prepared following the procedure of Example 1, utilizing however 180g of light mineral oil, 1556g. of deionized water and 10g. of 5 Emulsynt 1055 (polyglycerol-4-oleate and polyethylene-glycol-8 propylene glycol cocoate).

Example 4

A 0.4% anthralin formulation is prepared according to the proportions and procedure of Example 1, 10 adding however a total of 1g. of ascorbyl palmitate and 1.4g. tocopherol together with 1g. of butylated hydroxytoluene. The content of anthralin which is added is increased to 8.8g. and the water to 1629g. Finally, 2.09g. of sodium bisulfite and 12g. of 15 disodium ethylenediamine tetraacetic acid are added to the water phase prior to emulsification.

Example 5

Formulations of the following compositions are prepared in accordance with the procedure set forth in 20 Example 1.

		<u>% of Composition</u>			
	<u>Formulations:</u>	<u>5A</u>	<u>5B</u>	<u>5C</u>	<u>5D</u>
<u>Oil phase:</u>					
	mineral oil	6.0	6.0	6.0	6.0
25	paraffin	2.3	2.3	2.3	2.3
	petrolatum	2.3	2.3	2.3	2.3
	aluminum stearate	0.7	0.7	0.7	0.7
	glyceryl oleate	1.5	1.5	1.5	1.5
	anthralin	0.12	0.22	0.44	1.1
30	ascorbyl palmitate	0.05	0.05	0.05	0.05

-10-

octyldodecanol	3.0	3.0	3.0	3.0
salicylic acid	0.4	0.4	0.4	0.4
butylated hydroxy-				
toluene	0.05	0.05	0.05	0.05

5 Water phase:

deionized water	81.66	81.56	81.34	80.68
citric acid	0.9	0.9	0.9	0.9
Na ₂ EDTA	0.60	0.60	0.60	0.60
sodium bisulfite	0.10	0.10	0.10	0.10

10 Preservatives:

propyl paraben	0.15	0.15	0.15	0.15
methyl paraben	0.10	0.10	0.10	0.10
<u>Tocopherol</u>	0.07	0.07	0.07	0.07

-11-

CLAIMS

1. A topical anthralin cream composition in which the anthralin demonstrates improved stability, said composition comprising
 - 5 (a)(i) from about 0.05% to about 5%, by weight of the composition, of anthralin in (ii) a water:fluid hydrocarbon emulsion having an oil continuous phase wherein the weight ratio of water to fluid hydrocarbon is at least about 5:1;
 - 10 (b) an emulsifying amount up to about 3%, by weight of the composition, of at least one anionic emulsifying agent;
 - 15 (c) from about 0.02% to about 2% by weight of the composition, of at least one oil soluble anti-oxidant; and
 - (d) one or more water soluble components which satisfy at least one of the functional categories of
 - 20 (i) an acidic material in an amount of from about 0.5% to about 1%, by weight of the composition; and
 - (ii) at least one bifunctional sequestering agent in an amount of from about 0.02% to about 2%, by weight of the composition,both of said functional categories being satisfied.
- 25 30 2. A topical composition according to claim 1 wherein the oil soluble anti-oxidant component is one or more members selected from the group consisting of alpha tocopherol, alpha tocopherol acetate, ascorbyl palmitate, hydroquinone, butylated hydroxytoluene and butylated hydroxyanisole.



-12-

3. A topical composition according to claim 1 wherein the water soluble components include a sequestering agent which is one or more of disodium ethylenediamine tetraacetic acid, thiourea, thioacetic acid, 5 cysteine, tyrosine, nicotinic acid and sarcosine.

4. A topical composition according to claim 1 wherein the water soluble components include an acidic material which is one or more of citric acid, malic acid, salicylic acid and sodium metabisulfite.

10 5. A topical composition according to claim 1 wherein the water soluble components include disodium ethylenediamine tetraacetic acid as the sequestering agent and citric acid, salicylic acid and sodium metabisulfite as the acidic material.

15 6. A topical composition according to claim 1 wherein the anionic emulsifying agent is a metal soap.

7. A topical composition according to claim 6 wherein the metal salt is aluminum stearate.

20 8. A topical composition according to claim 6 wherein one or more members selected from the group consisting of fatty alcohols, glycerol esters, polyoxyalkylene esters and polyoxyalkylene ethers are present as a nonionic emulsifying agent.

25 9. A topical composition according to claim 8 wherein the hydrocarbon is a mixture of light mineral oil, paraffin, and petrolatum and the nonionic emulsifying agent is a polyoxyalkylene ester.



SEARCHED

-13-

10. A topical composition according to claim 1 wherein (i) the water:hydrocarbon ratio is at least 7:1 and the hydrocarbon is a mixture of light mineral oil, paraffin, and petrolatum; (ii) the oil soluble anti-
5 oxidant component is one or more members selected from the group consisting of alpha tocopherol, alpha tocopherol acetate, ascorbyl palmitate, hydroquinone, butylated hydroxytoluene and butylated hydroxyanisole; (iii) the water soluble components include a sequest-
10 ering agent which is one or more of disodium ethylenediamine tetraacetic acid, thiourea, thioacetic acid, cysteine, tyrosine, nicotinic acid and sarcosine, and an acidic material which is one or more of citric acid, salicylic acid and sodium metabisulfite; and (iv) the
15 anionic emulsifying agent is a metal soap; the composition also including at least one nonionic emulsifying agent selected from the group consisting of fatty alcohols, glycerol fatty acid esters, polyoxyalkylene fatty acid esters and polyoxyalkylene fatty alcohol
20 ethers.

11. A composition according to claim 1 comprising (i) from about 0.1 to about 1% anthralin in a water:hydrocarbon emulsion of about 6 to about 10% light mineral oil, from about 2% to about 3% petrolatum, from
25 about 2% to about 3% paraffin and from about 75% to about 85% water; said composition also comprising (ii) an emulsifying amount up to about 1% of a fatty acid metal soap, (iii) a total from of about 0.1 to about 0.2% of one or more oil soluble anti-oxidants, (iv) from
30 about 0.5 to about 1% of disodium ethylenediamine tetraacetic acid, (v) a total of from about 0.5 to about 1.5% of one, two, or three members selected from the group consisting of citric acid, salicylic acid, and sodium metabisulfite, (vi) from about 1 to about 5% of a higher alkanol and (vii) from about 1 to about 3% of a fatty acid monoester of glycerol or a polyglycerol.

-14-

12. A composition according to claim 1 comprising (i) from about 0.1 to about 1% anthralin in a water:hydrocarbon emulsion of about 6% light mineral oil, from about 2.2% to about 2.4% petrolatum, from 5 about 2.2% to about 2.4% paraffin and about 80% water; (ii) about 0.7% of aluminum distearate, (iii) about 0.07% tocopherol, about 0.05% of butylated hydroxytoluene and about 0.05% ascorbyl palmitate as oil soluble anti-oxidants, (iv) about 0.6 % of disodium 10 ethylenediamine tetraacetic acid, (v) about 0.9% of citric acid, (vi) about 0.4% salicylic acid, (vii) about 0.1% sodium metabisulfite, (viii) about 3% of octyl-dodecanol, and (ix) about 1.5% of polyglyceryl-4 oleate.

13. A composition according to claim 12 which 15 contains about 0.1% anthralin.

14. A composition according to claim 12 which contains about 0.2% anthralin.

15. A composition according to claim 12 which contains about 0.4% anthralin.

20 16. A composition according to claim 12 which contains about 1% anthralin.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US84/00896

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁸According to International Patent Classification (IPC) or to both National Classification and IPC **3**
424/346**A61K - 31/05; A61K-7/42**

II. FIELDS SEARCHED

Minimum Documentation Searched ⁴

Classification System	Classification Symbols
U.S.	424/346, 59
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸	

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴

Category ⁹	Citation of Document, ¹⁸ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	US, A, 4,287,214, published 1 September 1981, Van Scott et al.	ALL
Y	US, A, 3,924,004, published 2 December 1975 (See Col. 3, line 7-Col. 5, line 66), Chang et al.	ALL
Y	N, Caron et al., "High Pressure Liquid Chromatographic Determination of Anthralin In Ointments", <u>Journal of Pharmaceutical Sciences</u> , 70(11): 1205-1207 (1981)	ALL
Y	N, Huff et al., Physicians' Desk Reference, 34th Edition; pp.817, 1698-99 (1980)	ALL
A	US, A, 4,104,403, published 1 August 1978 Barker et al.	ALL
A	US, A, 4,203,969, published 20 May 1980, Yarrow et al.	ALL

¹⁵ Special categories of cited documents:¹⁶ "A" document defining the general state of the art which is not considered to be of particular relevance¹⁷ "E" earlier document but published on or after the international filing date¹⁸ "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)¹⁹ "O" document referring to an oral disclosure, use, exhibition or other means²⁰ "P" document published prior to the international filing date but later than the priority date claimed²¹ "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention²² "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step²³ "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.²⁴ "G" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search ²⁵

17 August 1984

Date of Mailing of this International Search Report ²⁶

27 AUG 1984

International Searching Authority ²⁷

ISA/US

Signature of Authorized Officer ²⁸

Joseph A. Lipovskey

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	N, Shroot et al., "Editorial: Anthralin -The Challenge", <u>British Journal of Dermatology</u> , 105, Supplement 20,3: pp. 3-5 (1981)	ALL
A	N, Krebs et al., "Structure Specificity of Antipsoriatic Anthrones", <u>British Journal of Dermatology</u> , 105, Supplement 20,3: pp 6-11 (1981)	ALL

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹⁰

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ¹¹

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
A	N, Cavey et al., "Anthralin: Chemical Instability and Glucose-6-Phosphate Dehydrogenase Inhibition", <u>British Journal of Dermatology</u> , 105 Supplement 20, 15 pp 15-19 (1981)	ALL
Y	N, Caron et al., "Determination of Anthralin In Commercial Ointments", <u>British Journal of Dermatology</u> , 105 Supplement 20, 57 pp. 57-58 (1981)	ALL
A	N, Van Scott et al., "New Chemical Stabilizers, Vehicles and Delivery Systems....", <u>British Journal of Dermatology</u> , 105 Supplement 20, 35, pp 35-38 (1981)	ALL
A	N, Whitfield et al., "Pharmaceutical Formulations of Anthralin," <u>British Journal of Dermatology</u> , 105, Supplement 20, 28, pp 28-32 (1981)	ALL
A	N, Ponec-Waelsh et al., "Further Studies of The Interaction...", <u>Arch. Derm. Forsch.</u> , 249, pp 142-152 (1974)	ALL